Clinical Trial Update: Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating YK012 for moderate to severe Systemic Lupus Erythematosus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• YK012

Snippet

Sponsor: Excyte Biopharma Ltd | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 1, Phase 2 | Status: RECRUITING